Name: Dr. Santosh Kumar Guru Assistant Professor santoshkumar.guru@niperhyd.ac.in, santoshkumarguru@gmail.com +91 40 23074750 Extn- 2049 Google Scholar Citations Click here for My Website

ADDRESS, ROOM NO

Department of Biological Sciences
Room No: 64
NIPER Hyderabad
Department of Pharmaceuticals (Govt. of India)
Balanagar, Hyderabad - 500037, TS, INDIA

Experience

1. Assistant Professor, Department of Biological Sciences at NIPER Hyderabad - February 2021 - Present
2. Senior Scientific Officer, CNCI-Kolkata, India, 2018-2021
3. Postdoctoral Research Associate, Umass Medical School, USA, 2016-2018.
4. Research Associate, IIIM-CSIR, Jammu, India, 2014-2016.
5. Senior Research Fellow, IIIM-CSIR-Jammu, India, 2011-2014
6. Junior Research Fellow, IIIM-CSIR-Jammu, India, 2009-2011
7. Laboratory Technician, RCPHS, Berhampur, Odisha, Jan. 2004-Jul. 2004

QUALIFICATION: (REVERSE CHRONOLOGICAL ORDER)

1. Ph.D: Life Science/Pharmaceutical Sciences-Pharmacology, GNDU/IIIM-CSIR
2. M.Pharm. (Pharmacology), RGPV, Bhopal
3. B. Pharm. (Pharmaceutical Sciences), BPUT, Odisha
4. D. Pharm. (Pharmaceutical Sciences), OSBP, Odisha

COURSES HANDLING(PHD/M.S(PHARM))

M.S. (Pharm.)
Drug Metabolism - PC 610
Molecular Toxicology- RT 630
General Pharmacology- PC-520
Pharmacological Assay & Screening- PC-611
Cell Biology- BT-520
Molecular Biology- BT-610
PhD
Receptor Mechanisms- PC-710
Current topics in Cancer Research - PC-920
Epigenetics and Disease- PC 860

PHD STUDENTS/MASTERS STUDENTS

PhD
Essha Chatterjee, UGC-JRF
Biswajit Dey, UGC-JRF
Hoshiyar Singh, NIPER-JEE
Miss. Swathilakshmi S, NIPER-JEE
Mr. Ankush Bansode, NIPER-JEE
Miss. K P Tryphena, NIPER-JEE
Miss. Bhagyashree Patra, NIPER-JEE
Miss. Aliva Naik, NIPER-JEE
Mr. Santanu Basak, NIPER-JEE
Mr. Deepanshu Mamgai, Integrated PhD

AWARDS / HONOURS

1. Postdoctoral Fellowship-NIH, at MCCB, Umass Medical School, MA, USA-01605
2. CSIR-JRF-2009 for Ph.D. Fellowship at IIIM, CSIR, Jammu, India-180001
3. Best paper award (2013) given by Indian Institute of Integrative medicine for the paper for “Tiron and Trolox potentiate the autophagic cell death induced by magnolol analog Ery5 by activation of Bax in HL-60 cells. Apoptosis 2013. 18:605-17.”
4. Best paper award (2014) given by Indian Institute of Integrative medicine for the paper for “Autophagy triggered by magnolol derivative negatively regulates angiogenesis.” Cell Death and Disease. 2013; 4:889.
5. Best paper award (2015) given by Indian Institute of Integrative medicine for the paper for “Pyrano-isochromanones as IL-6 inhibitors: Synthesis, in vitro and in vivo Ant arthritic Activity. Journal of Medicinal Chemistry 2014. 57,7085-7097.”
6. Best paper award (2016) given by Indian Institute of Integrative medicine for the paper for “Secalonic Acid-D Represses HIF1a/VEGF Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade.” Cancer Research. 2015; 75:2886-2896. ISSN: 1538-7445(Online), ISSN: 0008-5472(Print).
7. Qualified GATE 2007 and GATE 2009 | and 6th Rank in Orissa JEE-2007

RESEARCH AREAS/INTEREST

• My research group mainly focuses on basic and applied drug discovery in cancer biology
• Regulated Cell Death (RCD) Triad in Cancer Persistence
• Investigating onco-metabolism
• Decoding the Integrated Vesicular and Organellar Trafficking (IVOT) Pathways in Cancer
• To develop "transcription-focused" combination regimens
• Inhibiting Resistance Mechanisms

SPONSORED PROJECTS

NIL

FELLOWSHIPS / GRANTS

Fellowships:

1. Postdoctoral Fellowship-Umass Medical School, USA
2. JRF- 2009, CSIR-IIIM, Jammu, India
3. GATE-2007, IIT-Kanpur: For master's degree Fellowship

Grants:

Ongoing

1. Design, Synthesis, and Preclinical Validation of Selective CDK7/Cyclin H/MAT1 Inhibitors as a Potential Treatment for Triple-Negative Breast Cancer. As Principal Investigator, funded by ICMR for four years. (345 Lakhs)
2. Development of novel 2-amino pyrimidine-based molecular hybrids as selective CDK-9 inhibitors. As co- principal investigator, funded by ICMR, Rs 49 Lakhs
3. Ex-Vivo and Pre-Clinical Evaluation of the BCL-2 Inhibitor based Surface Engineered Onco-nanomedicines for the Leukemia Treatment. As co-principal investigator, ICMR-2025. Rs. 1.5 Cr.

Completed

1. Identification of the molecular reprogramming landscape of pre- and post-neoadjuvant chemotherapy in gastric cancer and its therapeutic implications. As Principal Investigator, funded by ICMR for three years. (57 Lakhs)
2. Noscapine and its derivatives for the treatment of drug-tolerant persister cells in breast cancer. As Principal Investigator, funded by ICMR for three years. (56 Lakhs)
3. Targeting chemoresistance in breast cancer. As Principal Investigator, funded by DHR for three years. (49 Lakhs)
4. Targeting CDK9 by coumarin-based inhibitors: Design, Preparation, and Biological Evaluation. As Joint Principal Investigator, funded by CRG-ANRF for three years. (34 Lakhs)
5. Analysis of the role of extracellular vesicles (exosomes) in drug-tolerant persister cells and its contribution to cancer-initiating cells in breast cancer. SERB-SRG: 2020-2022. As Principal Investigator, (28 Lakh)

PUBLICATIONS / BOOK CHAPTERS

View / Download

PATENTS

1. Vishwakarma RA, Bharate SB, Bhushan S, Yadav RR, Guru SK, Joshi P. 6-Aryl-4-phenyl amino quinazolines as phosphoinositide 3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2015128873A1, 0554DEL2014. Granted in US, EP - US10202374B2 (Feb. 2019). EP3110801B1 (January 2019).
2. Vishwakarma RA, Bharate SB, Kumar A, Singh B, Kumar A, Bhushan S, Hamid A, Joshi P, Guru SK, Kumar S, Hussain A, Qazi AK, Bharate SS, Sharma P, Saxena AK, Mondhe DM, Mahajan G, Wani Z. 10-Substituted colchicinoids as potent anticancer agents. WO2016059650A1, 2929DEL2014, Granted in US, EP- US9868695 (January 2018), EP3207026 (Nov 2018).
3. Bharate SB, Bhushan S, Mohammed S, Guru SK, Bharate SS, Kumar V, Mahajan G, Javed MM, Mondhe DM, Vishwakarma RA. Fused pyrimidines as isoform-selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof. WO2017090058A1, 3818DEL2015. Granted in US, EP- US20200031845A1. EP3380476A1.
4. Vishwakarma RA, Bharate SB, Bhushan S, Mondhe DM, Jain SK, Meena S, Guru SK, Pathania AS, Kumar S, Behl A, Mintoo MJ, Bharate SS, Joshi P. Cyclin-dependent kinase inhibition by 5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one analogs. Granted in US, EP - US9932327B2 (April 2018). EP2986605 (Nov 2017) WO2014170914A1, IN2013DE01142. [On Clinical trial for pancreatic cancer, 2020]

INVITED TALKS

NIL

LABORATORY FACILITIES DEVELOPED

• BSL-2 Established
• PDX-Mouse Model for TNBC
• Anti-Cancer Drug Screening

ADDITIONAL RESPONSIBILITIES

• Co-Chair Consumable Purchase Committee (2022-2025)
• Chair Library Information Centre, NIPER-Hyderabad (2022-2025)
• Chair Non-Consumable Purchase Committee (2024-2025)